The LamKap Bio group currently comprises three separate companies each dedicated to the development of a T cell or phagocytes and natural killer cells engaging bispecific antibody targeting a specific tumor-associated antigen.
- LamKap Bio alpha AG
- LamKap Bio beta AG
- LamKap Bio gamma AG
Each of these companies is working independently on one or more bsAb projects.
